CPHI 2025: linker innovation paves the way for a wave of new ADCs
Antibody-drug conjugate (ADC) developers say innovations to linkers, the proteins bridging antibodies to their therapeutic payloads, are opening the door…
All articles by Frankie Fattorini
Frankie Fattorini
Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.
-
-
CPHI 2025: ‘handprint’ metric bridges pharma sustainability and economic value
Pharma manufacturer Evonik is piloting a new ‘handprint’ metric to quantify the socioeconomic benefits of manufacturing practices, a move that…
-
CPHI 2025: directing AI-driven innovation to harness Europe’s data edge
Europe’s biopharma stakeholders should seek innovation through AI to meet the challenges of treatment resistance, drug affordability, and a creeping…
-
CPHI 2025: time for European biopharma to double down on innovation
Investors are urging Europe’s biopharma companies to embrace the continent’s long-established specialisation as an innovation hub as the route to…
-
China’s drugs offer lifeline for global pharma as it peers over the patent cliff
Out-licensing of clinical candidates from China has increased dramatically over the last five years, as the world’s pharma companies shore…
-
FDA ‘green list’ flagging illegal GLP-1RA compounders is long overdue
In the midst of the rising popularity of glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their compounded versions, the US Food…
-
Podcast: The FDA’s emerging aversion to advisory committees
Last month, the head of the US Food and Drug Administration's (FDA) Centre for Drug Evaluation and Research (CDER) George…
-
Disruption due for long-held assumptions in biopharma, says BIA chair
Foundational certainties of the biopharma industry may no longer hold true for the sector’s future as paradigm shifts reshape the…
-
NewCo licensing models are tipping deals in favour of China’s biotechs
As pharma companies continue to license candidates developed in China, experts say a particular licensing model is allowing the country's…
-
VPAG stalemate threatens to exclude innovative medicines from the UK
Stalled negotiations around the UK's Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) between the UK government and…